R R

What Is QuilliChew ER?

QuilliChew ER is a prescription central nervous system stimulant containing methylphenidate hydrochloride. It is an extended-release chewable tablet used to treat attention-deficit/hyperactivity disorder (ADHD). QuilliChew ER is intended for patients aged six years and older and is not recommended for younger children because of increased medication exposure and adverse reactions. The tablets provide a treatment option for patients who have difficulty swallowing conventional capsules or tablets. QuilliChew ER is classified as a Schedule II controlled substance because methylphenidate carries significant risks of misuse, abuse, and addiction. Treatment requires monitoring of cardiovascular health, growth in children, and behavioral changes.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is QuilliChew ER?

QuilliChew ER is a prescription central nervous system stimulant containing methylphenidate hydrochloride. It is an extended-release chewable tablet used to treat attention-deficit/hyperactivity disorder (ADHD). QuilliChew ER is intended for patients aged six years and older and is not recommended for younger children because of increased medication exposure and adverse reactions. The tablets provide a treatment option for patients who have difficulty swallowing conventional capsules or tablets. QuilliChew ER is classified as a Schedule II controlled substance because methylphenidate carries significant risks of misuse, abuse, and addiction. Treatment requires monitoring of cardiovascular health, growth in children, and behavioral changes.

read more about quillichew er ...

Copy this HTML:

Copy HTML Copied!

How Does QuilliChew ER Work?

QuilliChew ER contains methylphenidate, which increases the availability of dopamine and norepinephrine in the central nervous system. It blocks the reuptake of these neurotransmitters and influences signaling involved in attention, activity regulation, and impulse control. The exact mechanism responsible for methylphenidate's therapeutic effects in ADHD is not fully established. QuilliChew ER uses an extended-release formulation that provides medication exposure throughout the day after a morning dose. It does not cure ADHD, and treatment response varies according to the patient's symptoms, prescribed dose, and other aspects of ADHD management.

Who Can Receive QuilliChew ER for ADHD?

QuilliChew ER is approved for the treatment of ADHD. It is used in patients aged six years and older who require medication to manage symptoms such as inattention, hyperactivity, and impulsivity. The prescribing information does not recommend use in children younger than six years because they experience higher methylphenidate exposure and more adverse reactions at equivalent doses. Before treatment, clinicians assess cardiovascular history, family history of serious heart conditions, and the presence of motor or vocal tics. They also evaluate mental health history, growth patterns in children, and potential interactions with other medications. QuilliChew ER is not approved for treating unrelated learning or behavioral difficulties.

How Should QuilliChew ER Be Taken?

QuilliChew ER is taken orally once daily in the morning, with or without food. The recommended starting dose for patients aged six years and older is 20 mg daily. Doses may be adjusted weekly in increments of 10 mg, 15 mg, or 20 mg according to treatment response and tolerability. Daily doses above 60 mg are not recommended. The 20 mg and 30 mg tablets are functionally scored and can be divided into equal halves to provide 10 mg and 15 mg doses, respectively. The 40 mg tablet is not scored. QuilliChew ER should not be substituted for another methylphenidate product on a milligram-for-milligram basis without appropriate dose adjustment.

What Are the Side Effects and Warnings of QuilliChew ER?

Common stimulant-related adverse effects include decreased appetite, insomnia, nausea, abdominal discomfort, irritability, dizziness, increased heart rate, and elevated blood pressure. QuilliChew ER carries a boxed warning for abuse, misuse, and addiction, which can result in overdose or death. Serious risks include cardiovascular complications in patients with certain heart diseases, psychiatric reactions, slowed growth in children, and peripheral vasculopathy. Methylphenidate can also trigger acute angle-closure glaucoma in susceptible patients and increase intraocular pressure. QuilliChew ER contains phenylalanine from aspartame, which matters for patients with phenylketonuria. Chest pain, fainting, hallucinations, or sudden eye pain and blurred vision require prompt medical evaluation.

Common Questions About QuilliChew ER

Is QuilliChew ER the same as methylphenidate?

QuilliChew ER contains methylphenidate hydrochloride in an extended-release chewable tablet. Other methylphenidate products may have different release characteristics and dosing instructions.

Can QuilliChew ER tablets be split?

Yes. The 20 mg and 30 mg tablets are scored and can be divided into equal halves. The 40 mg tablet is not scored.

Is QuilliChew ER a controlled substance?

Yes. QuilliChew ER is a Schedule II controlled substance because methylphenidate has significant potential for misuse and addiction.

Can QuilliChew ER affect eyesight?

Yes. QuilliChew ER can increase intraocular pressure and may trigger acute angle-closure glaucoma in susceptible patients. Sudden eye pain or visual changes require urgent assessment.

References

DailyMed - QUILLICHEW ER (methylphenidate hydrochloride) chewable extended-release tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=defc1205-8e90-4b1e-b862-05e4c35c7364. Date Accessed November 3, 2026.

Methylphenidate. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK547941/. Date Accessed November 3, 2026.

Methylphenidate. MedlinePlus. https://medlineplus.gov/druginfo/meds/a682188.html. Date Accessed November 3, 2026.

Methylphenidate. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Methylphenidate. Date Accessed November 3, 2026.

Methylphenidate. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK482451/. Date Accessed November 3, 2026.